世界のバイオ医薬品受託製造(CMO)・受託研究(CRO)市場2021-2028:原料別(哺乳類、非哺乳類)、サービスタイプ別(委託製造、委託研究)、製品別

◆英語タイトル:Biopharmaceutical CMO And CRO Market Size, Share & Trends Analysis Report By Source (Mammalian, Non-mammalian), By Service Type (Contract Manufacturing, Contract Research), By Product, And Segment Forecasts, 2021 - 2028
◆商品コード:GV21MC087
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2021年1月20日
◆ページ数:240
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥678,300見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥792,300見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,020,300見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Grand View Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

グランドビューリサーチ社は、世界のバイオ医薬品受託製造(CMO)・受託研究(CRO)市場規模が2028年までに492憶ドルに達すると予測しています。2021年から2028年までに年平均7.6%成長する見通しです。本調査レポートでは、バイオ医薬品受託製造(CMO)・受託研究(CRO)の世界市場について調査・分析し、調査手法、エグゼクティブサマリー、市場変動・動向・範囲、原料別(哺乳類、非哺乳類)分析、サービスタイプ別(委託製造、委託研究)分析、製品別(生物製剤、バイオシミラー)分析、地域別分析、競争状況などを掲載しています。
・調査手法
・エグゼクティブサマリー
・市場変動・動向・範囲
・バイオ医薬品受託製造(CMO)・受託研究(CRO)の世界市場規模:原料別(哺乳類、非哺乳類)
・バイオ医薬品受託製造(CMO)・受託研究(CRO)の世界市場規模:サービスタイプ別(委託製造、委託研究)
・バイオ医薬品受託製造(CMO)・受託研究(CRO)の世界市場規模:製品別(生物製剤、バイオシミラー)
・バイオ医薬品受託製造(CMO)・受託研究(CRO)の世界市場規模:地域別
・競争状況
【レポートの概要】

Biopharmaceutical CMO & CRO Market Growth & Trends

The global biopharmaceutical CMO and CRO market size is expected to reach USD 49.2 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 7.6% from 2021 to 2028. The market is significantly driven by the growing interest of conventional drug developers in biological therapeutics. At present, outsourcing has become a cost-saving strategy for small to medium-sized bio-manufacturers as it helps in eliminating the need for establishing costly specialized facilities or hiring and training personnel.

The global market for biopharmaceutical CMO and CRO is expected to thrive during the pandemic owing to positive pipeline development across modalities. For instance, Lonza and Moderna announced a ten-year collaboration for the commercial manufacturing of the COVID-19 vaccine. Such developments compensated for minor delays in clinical trials that occurred during the first half of 2020. The contract manufacturing organization segment is projected to unlock lucrative growth opportunities over the foreseeable future.

The decline in R&D productivity and increased development costs have resulted in high pressure on biopharmaceutical manufacturers pertaining to short-term earnings and profit margins. This, in turn, has created lucrative opportunities for the CMOs and CROs to accelerate their business operations.

The mammalian source segment dominated the market in 2020. CMOs are engaged in standardizing their mammalian systems, thereby driving the revenue growth in the mammalian segment. Plant-based expression systems are developed and explored as a cost-effective alternative for the production of large molecules.

The robustness of venture capital investments is one of the important supportive factors that has created opportunities for the growth of CMOs. Venture capital funds are considered more reliable than public equity. An increase in the availability of venture funds for life sciences is expected to bolster the growth of CMOs.

However, these CMOs and CROs are facing competition from in-house departments of pharmaceutical and biotechnology companies. Several big pharma companies like Novartis announced to keep their biomanufacturing process in-house.

Some key CMOs are Lonza; Boehringer Ingelheim GmbH; Patheon; Samsung BioLogics; and FUJIFILM Diosynth Biotechnologies U.S.A., Inc. The key players are involved in establishing mutually beneficial alliances with other emerging CMOs to scale up their production capabilities.

Biopharmaceutical CMO & CRO Market Report Highlights

• Based on source, mammalian cell line-based bioproduction system accounted for the largest revenue share of 54.0% in 2020 due to the growth in mammalian system titers and yields

• By service type, contract manufacturing services accounted for the largest share of 57.7% in 2020 owing to the presence of a wide range of services from cell line development to the final packaging of the product

• Contract research services are expected to expand at the fastest CAGR of 8.4% over the forecast period. This can be attributed to increasing investment in research programs for the development of novel therapeutics

• In terms of product, biologics held the largest share of 81.8% in 2020. In recent times, biologics manufacturing is becoming more specialized, as a result of which CMOs have become an integral part of the biologics production strategies of clients

• North America held the largest share of 33.8% in 2020. The North American biopharmaceutical research industry is recognized as a leader in biopharmaceutical innovations. Several biopharma companies from the U.S. are considering Asian countries for the development of pharma products. This is primarily due to the growing costs of R&D in their home country and the presence of low-cost production facilities and cheap labor in Asian countries

【レポートの目次】

Table of Contents

Chapter 1 Research Methodology
1.1 Market Segmentation & Scope
1.2 Market Definition
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources & third party perspectives
1.3.4 Primary research
1.4 Information Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Data Visualization
1.6 Data Validation & Publishing
Chapter 2 Executive Summary
2.1 Biopharmaceutical CMO & CRO Market Outlook, 2016-2028
Chapter 3 Industry Outlook: Market Variables, Trends, & Scope
3.1 Penetration &Growth Prospect Mapping For Contract Manufacturing Service, 2018
3.2 Trend Analysis
3.2.1 Source trend
3.2.2 Service trend
3.2.3 Product trend
3.2.4 Regional trend
3.3 Biopharmaceutical CMO & CRO Market: Market Dynamics
3.3.1 Market driver analysis
3.3.1.1 Rising investment by CMOs for capacity expansion
3.3.1.2 Commercial success of biopharmaceuticals and consequent increased demand for the biopharmaceuticals
3.3.1.3 Robust biopharmaceuticals pipeline
3.3.1.4 Cost and time-saving benefits offered by contract services
3.3.2 Market restraint analysis
3.3.2.1 Limited outsourcing amongst well-established biopharmaceutical manufacturer
3.4 Key Opportunity Analysis
3.4.1 Rising funds in biopharmaceutical industry
3.4.2 Mergers & acquisition for facility expansion
3.4.2 Growing demand for protein therapeutics
3.5 Industry Analysis – Porter’s
3.5.1 Supplier Power: Substantial number of suppliers for bioprocessing equipment contributes to the low supplier power
3.5.2 Buyer Power: Fragmented nature of the biopharmaceutical industry has led to the moderate bargaining power of buyers
3.5.3 Substitution Threat: High due to the presence of several big pharma companies
3.5.4 New Entrants Threat: The presence of established players coupled with the need of adequate capacity results in a moderate threat of new entrants
3.5.5 Competitive Rivalry: High due to fragmented nature of the market
3.6 Biopharmaceuticals CMO & CRO-SWOT Analysis, By PEST
3.6.1 Political landscape
3.6.2 Economic landscape
3.6.3 Social landscape
3.6.4 Technology landscape
3.7 Biopharmaceuticals CMO & CRO Market: Company Share Analysis
3.8 Competitive Landscape
3.8.1 Strategy Framework
3.8.2 Company Categorization
3.8.3 New Entrants
3.8.4 Mature Players & Leaders
3.9 Trends In Biopharmaceutical Industry
3.10 R&D Landscape Of Biopharmaceuticals
3.11 Customer Relationship Management In Contract Manufacturing
3.11.1 Selection process of CMO
3.11.2 Operations and quality oversight of CMOs
Chapter 4 Biopharmaceuticals CMO & CRO Market: Source Estimates & Trend Analysis
4.1 Market: Source Movement Analysis
4.2 Mammalian Source
4.2.1 Market, 2016 – 2028 (USD Million)
4.3 Non-mammalian Source
4.3.1 Market, 2016 – 2028 (USD Million)
Chapter 5 Biopharmaceuticals CMO & CRO Market: Service Type Estimates & Trend Analysis
5.1 Market: Service Type Movement Analysis
5.2 Contract Manufacturing
5.2.1 Market, 2016 – 2028 (USD Million)
5.2.2 Process development
5.2.2.1 Market, 2016 – 2028 (USD Million)
5.2.2.2 Downstream processing
5.2.2.2.1 Market, 2016 – 2028 (USD Million)
5.2.2.3 Upstream processing
5.2.2.3.1 Market, 2016 – 2028 (USD Million)
5.2.3 Fill & finish operations
5.2.3.1 Market, 2016 – 2028 (USD Million)
5.2.4 Analytical & QC testing
5.2.4.1 Market, 2016 – 2028 (USD Million)
5.2.5 Packaging
5.2.5.1 Market, 2016 – 2028 (USD Million)
5.3 Contract Research
5.3.1 Market, 2016 – 2028 (USD Million)
5.3.2 Oncology
5.3.2.1 Global oncology market, 2016 – 2028 (USD Million)
5.3.3 Inflammation & immunology
5.3.3.1 Market, 2016 – 2028 (USD Million)
5.3.4 Cardiology
5.3.4.1 Market, 2016 – 2028 (USD Million)
5.3.5 Neuroscience
5.3.5.1 Market, 2016 – 2028 (USD Million)
5.3.6 Others
5.3.6.1 Market, 2016 – 2028 (USD Million)
Chapter 6 Biopharmaceuticals CMO & CRO Market: Product Estimates & Trend Analysis
6.1 Global Biopharmaceuticals CMO & CRO Market: Product Movement Analysis
6.2 Biologics
6.2.1 Global biologics market, 2016 – 2028 (USD Million)
6.2.2 Monoclonal Antibodies
6.2.2.1 Global monoclonal antibodies market, 2016 – 2028 (USD Million)
6.2.3 Recombinant proteins
6.2.3.1 Global recombinant proteins market, 2016 – 2028 (USD Million)
6.2.4 Vaccines
6.2.4.1 Global vaccines market, 2016 – 2028 (USD Million)
6.2.5 Antisense, RNAi, & molecular therapy
6.2.5.1 Global antisense, RNAi, &molecular therapy market, 2016 – 2028 (USD Million)
6.2.6 Others
6.2.6.1 Global other products market, 2016 – 2028 (USD Million)
6.3 Biosimilars
6.3.1 Global biosimilars market, 2016 – 2028 (USD Million)
Chapter 7 Biopharmaceuticals CMO & CRO Market: Regional Estimates & Trend Analysis, by Service Type, Source, & Product
7.1 Market Share By Region, 2020 & 2028
7.2 North America
7.2.1 Market, 2016 – 2028 (USD Million)
7.2.2 U.S.
7.2.2.1 Market, by source, 2016 – 2028 (USD Million)
7.2.2.2 Market, by service type, 2016 – 2028 (USD Million)
7.2.2.3 Market, by product, 2016 – 2028 (USD Million)
7.2.3 Canada
7.2.3.1 Market, by source, 2016 – 2028 (USD Million)
7.2.3.2 Market, by service type, 2016 – 2028 (USD Million)
7.2.3.3 Market, by product, 2016 – 2028 (USD Million)
7.3 Europe
7.3.1 Market, 2016 – 2028 (USD Million)
7.3.2 Germany
7.3.2.1 Market, by source, 2016 – 2028 (USD Million)
7.3.2.2 Market, by service type, 2016 – 2028 (USD Million)
7.3.2.3 Market, by product, 2016 – 2028 (USD Million)
7.3.3 France
7.3.3.1 Market, by source, 2016 – 2028 (USD Million)
7.3.3.2 Market, by service type, 2016 – 2028 (USD Million)
7.3.3.3 Market, by product, 2016 – 2028 (USD Million)
7.4 Asia Pacific
7.4.1 Market, 2016 – 2028 (USD Million)
7.4.2 China
7.4.2.1 Market, by source, 2016 – 2028 (USD Million)
7.4.2.2 Market, by service type, 2016 – 2028 (USD Million)
7.4.2.3 Market, by product, 2016 – 2028 (USD Million)
7.4.3 India
7.4.3.1 Market, by source, 2016 – 2028 (USD Million)
7.4.3.2 Market, by service type, 2016 – 2028 (USD Million)
7.4.3.3 Market, by product, 2016 – 2028 (USD Million)
7.5 Latin America
7.5.1 Market, 2016 – 2028 (USD Million)
7.5.2 Brazil
7.5.2.1 Market, by source, 2016 – 2028 (USD Million)
7.5.2.2 Market, by service type, 2016 – 2028 (USD Million)
7.5.2.3 Market, by product, 2016 – 2028 (USD Million)
7.6 Middle East & Africa (MEA)
7.6.1 Market, 2016 – 2028 (USD Million)
7.6.2 South Africa
7.6.2.1 Market, by source, 2016 – 2028 (USD Million)
7.6.2.2 Market, by service type, 2016 – 2028 (USD Million)
7.6.2.3 Market, by product, 2016 – 2028 (USD Million)
Chapter 8 Competitive Landscape
8.1 Company Profiles
8.1.1 Boehringer Ingelheim GmbH
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Product benchmarking
8.1.1.4 Strategic initiatives
8.1.2 LONZA
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Product benchmarking
8.1.2.4 Strategic initiatives
8.1.3 Inno Biologics Sdn Bhd
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Product benchmarking
8.1.3.4 Strategic initiatives
8.1.4 Rentschler Biotechnologie GmbH
8.1.4.1 Company overview
8.1.4.2 Financial performance
8.1.4.3 Product benchmarking
8.1.4.4 Strategic initiatives
8.1.5 JRS PHARMA
8.1.5.1 Company overview
8.1.5.1.1 CELONIC AG
8.1.5.2 Financial performance
8.1.5.2.1 Financial performance
8.1.5.3 Product benchmarking
8.1.5.4 Strategic initiatives
8.1.6 BIOMEVA GmbH
8.1.6.1 Company overview
8.1.6.2 Financial performance
8.1.6.3 Product benchmarking
8.1.6.4 Strategic initiatives
8.1.7 ProBioGen
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Product benchmarking
8.1.7.4 Strategic initiatives
8.1.8 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Product benchmarking
8.1.8.4 Strategic initiatives
8.1.9 TOYOBO CO., LTD.
8.1.9.1 Company overview
8.1.9.2 Financial performance
8.1.9.3 Product benchmarking
8.1.9.4 Strategic initiatives
8.1.10 Samsung BioLogics
8.1.10.1 Company overview
8.1.10.2 Financial performance
8.1.10.3 Product benchmarking
8.1.10.4 Strategic initiatives
8.1.11 Patheon
8.1.11.1 Company overview
8.1.11.1.1 DPx
8.1.11.2 Financial performance
8.1.11.3 Product benchmarking
8.1.11.4 Strategic initiatives
8.1.12 CMC Biologics
8.1.12.1 Company overview
8.1.12.2 Financial performance
8.1.12.3 Product benchmarking
8.1.12.4 Strategic initiatives
8.1.13 Binex Co., Ltd.
8.1.13.1 Company overview
8.1.13.2 Financial performance
8.1.13.3 Product benchmarking
8.1.13.4 Strategic initiatives
8.1.14 WuXi Biologics
8.1.14.1 Company overview
8.1.14.2 Financial performance
8.1.14.3 Product benchmarking
8.1.14.4 Strategic initiatives
8.1.15 AbbVie, Inc.
8.1.15.1 Company overview
8.1.15.2 Financial performance
8.1.15.3 Product benchmarking
8.1.15.4 Strategic initiatives
8.1.16 Charles River Laboratories International, Inc
8.1.16.1 Company overview
8.1.16.2 Financial performance
8.1.16.3 Product benchmarking
8.1.16.4 Strategic initiatives
8.1.17 ICON plc.
8.1.17.1 Company overview
8.1.17.2 Financial performance
8.1.17.3 Product benchmarking
8.1.17.4 Strategic initiatives
8.1.18 Pharmaceutical Product Development, LLC
8.1.18.1 Company overview
8.1.18.2 Financial performance
8.1.18.3 Product benchmarking
8.1.18.4 Strategic initiatives
8.1.19 LabCorp
8.1.19.1 Company overview
8.1.19.2 Financial performance
8.1.19.3 Product benchmarking
8.1.19.4 Strategic initiatives
8.1.20 Parexel International Corporation
8.1.20.1 Company overview
8.1.20.2 Financial performance
8.1.20.3 Product benchmarking
8.1.20.4 Strategic initiatives
8.1.21 PRA Health Sciences
8.1.21.1 Company overview
8.1.21.2 Financial performance
8.1.21.3 Product benchmarking
8.1.21.4 Strategic initiatives

List of Tables

TABLE 1 2020 pipeline of biologics
TABLE 2 Some commercially available biopharmaceuticals and biologics produced using both mammalian & non-mammalian cell lines
TABLE 3 Some commercially available biopharmaceuticals and biologics produced using only mammalian cell lines
TABLE 4 Some biopharmaceuticals produced using S. cerevisiae
TABLE 5 Some commercially available biopharmaceuticals and biologics produced using only microbial cell lines
TABLE 6 Some commercially available monoclonal antibody products
TABLE 7 Number of mAbs products by indication area, 2015
TABLE 8 Time and budget requirement for different stages of vaccine development
TABLE 9 North America biopharmaceuticals CMO & CRO market estimates, by source, 2016 - 2020 (USD Million)
TABLE 10 North America biopharmaceuticals CMO & CRO market forecasts, by source, 2021 - 2028 (USD Million)
TABLE 11 North America biopharmaceuticals CMO & CRO market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 12 North America biopharmaceuticals CMO & CRO market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 13 North America biopharmaceuticals contract manufacturing market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 14 North America biopharmaceuticals contract manufacturing market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 15 North America biopharmaceuticals process development market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 16 North America biopharmaceuticals process development market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 17 North America biopharmaceuticals contract research market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 18 North America biopharmaceuticals contract research market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 19 North America biopharmaceuticals CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 20 North America biopharmaceuticals CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 21 North America biologics CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 22 North America biologics CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 23 U.S. biopharmaceuticals CMO & CRO market estimates, by source, 2016 - 2020 (USD Million)
TABLE 24 U.S. biopharmaceuticals CMO & CRO market forecasts, by source, 2021 - 2028 (USD Million)
TABLE 25 U.S. biopharmaceuticals CMO & CRO market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 26 U.S. biopharmaceuticals CMO & CRO market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 27 U.S. biopharmaceuticals contract manufacturing market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 28 U.S. biopharmaceuticals contract manufacturing market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 29 U.S. biopharmaceuticals process development market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 30 U.S. biopharmaceuticals process development market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 31 U.S. biopharmaceuticals contract research market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 32 U.S. biopharmaceuticals contract research market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 33 U.S. biopharmaceuticals CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 34 U.S. biopharmaceuticals CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 35 U.S. biologics CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 36 U.S. biologics CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 37 Canada biopharmaceuticals CMO & CRO market estimates, by source, 2016 - 2020 (USD Million)
TABLE 38 Canada biopharmaceuticals CMO & CRO market forecasts, by source, 2021 - 2028 (USD Million)
TABLE 39 Canada biopharmaceuticals CMO & CRO market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 40 Canada biopharmaceuticals CMO & CRO market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 41 Canada biopharmaceuticals contract manufacturing market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 42 Canada biopharmaceuticals contract manufacturing market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 43 Canada biopharmaceuticals process development market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 44 Canada biopharmaceuticals process development market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 45 Canada biopharmaceuticals contract research market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 46 Canada biopharmaceuticals contract research market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 47 Canada biopharmaceuticals CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 48 Canada biopharmaceuticals CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 49 Canada biologics CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 50 Canada biologics CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 51 Europe biopharmaceuticals CMO & CRO market estimates, by source, 2016 - 2020 (USD Million)
TABLE 52 Europe biopharmaceuticals CMO & CRO market forecasts, by source, 2021 - 2028 (USD Million)
TABLE 53 Europe biopharmaceuticals CMO & CRO market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 54 Europe biopharmaceuticals CMO & CRO market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 55 Europe biopharmaceuticals contract manufacturing market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 56 Europe biopharmaceuticals contract manufacturing market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 57 Europe biopharmaceuticals process development market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 58 Europe biopharmaceuticals process development market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 59 Europe biopharmaceuticals contract research market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 60 Europe biopharmaceuticals contract research market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 61 Europe biopharmaceuticals CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 62 Europe biopharmaceuticals CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 63 Europe biologics CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 64 Europe biologics CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 65 Germany biopharmaceuticals CMO & CRO market estimates, by source, 2016 - 2020 (USD Million)
TABLE 66 Germany biopharmaceuticals CMO & CRO market forecasts, by source, 2021 - 2028 (USD Million)
TABLE 67 Germany biopharmaceuticals CMO & CRO market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 68 Germany biopharmaceuticals CMO & CRO market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 69 Germany biopharmaceuticals contract manufacturing market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 70 Germany biopharmaceuticals contract manufacturing market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 71 Germany biopharmaceuticals process development market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 72 Germany biopharmaceuticals process development market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 73 Germany biopharmaceuticals contract research market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 74 Germany biopharmaceuticals contract research market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 75 Germany biopharmaceuticals CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 76 Germany biopharmaceuticals CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 77 Germany biologics CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 78 Germany biologics CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 79 France biopharmaceuticals CMO & CRO market estimates, by source, 2016 - 2020 (USD Million)
TABLE 80 France biopharmaceuticals CMO & CRO market forecasts, by source, 2021 - 2028 (USD Million)
TABLE 81 France biopharmaceuticals CMO & CRO market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 82 France biopharmaceuticals CMO & CRO market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 83 France biopharmaceuticals contract manufacturing market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 84 France biopharmaceuticals contract manufacturing market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 85 France biopharmaceuticals process development market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 86 France biopharmaceuticals process development market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 87 France biopharmaceuticals contract research market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 88 France biopharmaceuticals contract research market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 89 France biopharmaceuticals CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 90 France biopharmaceuticals CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 91 France biologics CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 92 France biologics CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 93 Asia Pacific biopharmaceuticals CMO & CRO market estimates, by source, 2016 - 2020 (USD Million)
TABLE 94 Asia Pacific biopharmaceuticals CMO & CRO market forecasts, by source, 2021 - 2028 (USD Million)
TABLE 95 Asia Pacific biopharmaceuticals CMO & CRO market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 96 Asia Pacific biopharmaceuticals CMO & CRO market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 97 Asia Pacific biopharmaceuticals contract manufacturing market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 98 Asia Pacific biopharmaceuticals contract manufacturing market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 99 Asia Pacific biopharmaceuticals process development market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 100 Asia Pacific biopharmaceuticals process development market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 101 Asia Pacific biopharmaceuticals contract research market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 102 Asia Pacific biopharmaceuticals contract research market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 103 Asia Pacific biopharmaceuticals CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 104 Asia Pacific biopharmaceuticals CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 105 Asia Pacific biologics CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 106 Asia Pacific biologics CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 107 China biopharmaceuticals CMO & CRO market estimates, by source, 2016 - 2020 (USD Million)
TABLE 108 China biopharmaceuticals CMO & CRO market forecasts, by source, 2021 - 2028 (USD Million)
TABLE 109 China biopharmaceuticals CMO & CRO market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 110 China biopharmaceuticals CMO & CRO market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 111 China biopharmaceuticals contract manufacturing market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 112 China biopharmaceuticals contract manufacturing market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 113 China biopharmaceuticals process development market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 114 China biopharmaceuticals process development market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 115 China biopharmaceuticals contract research market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 116 China biopharmaceuticals contract research market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 117 China biopharmaceuticals CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 118 China biopharmaceuticals CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 119 China biologics CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 120 China biologics CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 121 India biopharmaceuticals CMO & CRO market estimates, by source, 2016 - 2020 (USD Million)
TABLE 122 India biopharmaceuticals CMO & CRO market forecasts, by source, 2021 - 2028 (USD Million)
TABLE 123 India biopharmaceuticals CMO & CRO market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 124 India biopharmaceuticals CMO & CRO market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 125 India biopharmaceuticals contract manufacturing market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 126 India biopharmaceuticals contract manufacturing market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 127 India biopharmaceuticals process development market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 128 India biopharmaceuticals process development market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 129 India biopharmaceuticals contract research market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 130 India biopharmaceuticals contract research market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 131 India biopharmaceuticals CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 132 India biopharmaceuticals CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 133 India biologics CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 134 India biologics CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 135 Latin America biopharmaceuticals CMO & CRO market estimates, by source, 2016 - 2020 (USD Million)
TABLE 136 Latin America biopharmaceuticals CMO & CRO market forecasts, by source, 2021 - 2028 (USD Million)
TABLE 137 Latin America biopharmaceuticals CMO & CRO market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 138 Latin America biopharmaceuticals CMO & CRO market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 139 Latin America biopharmaceuticals contract manufacturing market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 140 Latin America biopharmaceuticals contract manufacturing market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 141 Latin America biopharmaceuticals process development market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 142 Latin America biopharmaceuticals process development market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 143 Latin America biopharmaceuticals contract research market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 144 Latin America biopharmaceuticals contract research market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 145 Latin America biopharmaceuticals CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 146 Latin America biopharmaceuticals CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 147 Latin America biologics CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 148 Latin America biologics CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 149 Brazil biopharmaceuticals CMO & CRO market estimates, by source, 2016 - 2020 (USD Million)
TABLE 150 Brazil biopharmaceuticals CMO & CRO market forecasts, by source, 2021 - 2028 (USD Million)
TABLE 151 Brazil biopharmaceuticals CMO & CRO market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 152 Brazil biopharmaceuticals CMO & CRO market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 153 Brazil biopharmaceuticals contract manufacturing market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 154 Brazil biopharmaceuticals contract manufacturing market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 155 Brazil biopharmaceuticals process development market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 156 Brazil biopharmaceuticals process development market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 157 Brazil biopharmaceuticals contract research market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 158 Brazil biopharmaceuticals contract research market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 159 Brazil biopharmaceuticals CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 160 Brazil biopharmaceuticals CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 161 Brazil biologics CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 162 Brazil biologics CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 163 MEA biopharmaceuticals CMO & CRO market estimates, by source, 2016 - 2020 (USD Million)
TABLE 164 MEA biopharmaceuticals CMO & CRO market forecasts, by source, 2021 - 2028 (USD Million)
TABLE 165 MEA biopharmaceuticals CMO & CRO market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 166 MEA biopharmaceuticals CMO & CRO market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 167 MEA biopharmaceuticals contract manufacturing market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 168 MEA biopharmaceuticals contract manufacturing market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 169 MEA biopharmaceuticals process development market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 170 MEA biopharmaceuticals process development market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 171 MEA biopharmaceuticals contract research market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 172 MEA biopharmaceuticals contract research market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 173 MEA biopharmaceuticals CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 174 MEA biopharmaceuticals CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 175 MEA biologics CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 176 MEA biologics CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 177 South Africa biopharmaceuticals CMO & CRO market estimates, by source, 2016 - 2020 (USD Million)
TABLE 178 South Africa biopharmaceuticals CMO & CRO market forecasts, by source, 2021 - 2028 (USD Million)
TABLE 179 South Africa biopharmaceuticals CMO & CRO market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 180 South Africa biopharmaceuticals CMO & CRO market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 181 South Africa biopharmaceuticals contract manufacturing market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 182 South Africa biopharmaceuticals contract manufacturing market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 183 South Africa biopharmaceuticals process development market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 184 South Africa biopharmaceuticals process development market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 185 South Africa biopharmaceuticals contract research market estimates, by service type, 2016 - 2020 (USD Million)
TABLE 186 South Africa biopharmaceuticals contract research market forecasts, by service type, 2021 - 2028 (USD Million)
TABLE 187 South Africa biopharmaceuticals CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 188 South Africa biopharmaceuticals CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)
TABLE 189 South Africa biologics CMO & CRO market estimates, by product, 2016 - 2020 (USD Million)
TABLE 190 South Africa biologics CMO & CRO market forecasts, by product, 2021 - 2028 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market segmentation & scope
FIG. 8 Biopharmaceutical CMO & CRO market outlook, 2016 - 2028
FIG. 9 Market trends & outlook
FIG. 10 Penetration & growth prospect mapping for contract manufacturing service, 2020
FIG. 11 Market driver relevance analysis (Current & future impact)
FIG. 12 Cumulative success rate comparison of biologics with small molecules over time
FIG. 13 Number of biologics investigational new drugs, 2005 - 2015
FIG. 14 Number of Reference Products by U.S. Biosimilars Launchable Dates
FIG. 15 Market restraint relevance analysis (Current & future impact)
FIG. 16 Risk associated with outsourcing services
FIG. 17 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 19 Porter’s Five Forces Analysis
FIG. 20 Company market share analysis
FIG. 21 Strategy framework
FIG. 22 Participant categorization
FIG. 23 CMO selection process
FIG. 24 Trends in the biopharmaceutical industry
FIG. 25 R&D process of biopharmaceutical development
FIG. 26 Development phases where outsourcing partners are engaged
FIG. 27 Global biopharmaceuticals CMO & CRO market: Source outlook key takeaways
FIG. 28 Global Biopharmaceuticals CMO & CRO market: Source movement analysis
FIG. 29 Global mammalian source market, 2016 - 2028 (USD Million)
FIG. 30 Global mammalian source market, 2016 - 2028 (USD Million)
FIG. 31 Global biopharmaceuticals CMO & CRO market: Service type outlook key takeaways
FIG. 32 Global biopharmaceuticals CMO & CRO market: Service type movement analysis
FIG. 33 Global contract manufacturing market, 2016 - 2028 (USD Million)
FIG. 34 Percentage of biomanufacturers outsourcing some activity of upstream and downstream processing, 2011 - 2016
FIG. 35 Global process development market, 2016 - 2028 (USD Million)
FIG. 36 Global downstream processing market, 2016 - 2028 (USD Million)
FIG. 37 Global upstream processing market, 2016 - 2028 (USD Million)
FIG. 38 Global fill & finish operations market, 2016 - 2028 (USD Million)
FIG. 39 Global analytical & QC testing market, 2016 - 2028 (USD Million)
FIG. 40 Global contract packaging market, 2016 - 2028 (USD Million)
FIG. 41 Breakdown of the general CRO industry by type of service
FIG. 42 Initial attributes that play a key role in CRO engagement
FIG. 43 Post-engagement attributes that play a key role in CRO engagement
FIG. 44 Global contract research market, 2016 - 2028 (USD Million)
FIG. 45 Global oncology market, 2016 - 2028 (USD Million)
FIG. 46 Global inflammation & immunology market, 2016 - 2028 (USD Million)
FIG. 47 Global cardiology market, 2016 - 2028 (USD Million)
FIG. 48 Global neuroscience market, 2016 - 2028 (USD Million)
FIG. 49 Global other CRO services market, 2016 - 2028 (USD Million)
FIG. 50 Global biopharmaceuticals CMO & CRO market: Product outlook key takeaways
FIG. 51 Global biopharmaceuticals CMO & CRO market: Product movement analysis
FIG. 52 Global biologics market, 2016 - 2028 (USD Million)
FIG. 53 Year-wise annual approvals for maAbs products which are currently marketed in U.S./EU
FIG. 54 Share of mAbs-related R&D programs at different pipeline phases, 2015
FIG. 55 Global monoclonal antibodies market, 2016 - 2028 (USD Million)
FIG. 56 Comparison of R&D biotech pipeline expansion for recombinant products
FIG. 57 Global recombinant proteins market, 2016 - 2028 (USD Million)
FIG. 58 Global vaccines market, 2016 - 2028 (USD Million)
FIG. 59 Global antisense, RNAi, & molecular therapy market, 2016 - 2028 (USD Million)
FIG. 60 Global other products market, 2016 - 2028 (USD Million)
FIG. 61 Global biosimilars market, 2016 - 2028 (USD Million)
FIG. 62 Regional market place: Key takeaway
FIG. 63 Comparison of biopharmaceutical manufacturing facilities region and country wise
FIG. 64 Biopharmaceuticals CMO & CRO regional outlook, 2020 & 2028
FIG. 65 North America biopharmaceuticals CMO & CRO market, 2016 - 2028 (USD Million)
FIG. 66 Number of U.S. pharmaceutical outsourcing M&A transactions
FIG. 67 Biopharmaceuticals goods export growth comparison between 2011 and 2014
FIG. 68 U.S. biopharmaceuticals CMO & CRO market, 2016 - 2028 (USD Million)
FIG. 69 Pros and cons of Canadian pharmaceutical & biopharmaceutical industry
FIG. 70 Canada biopharmaceuticals CMO & CRO market, 2016 - 2028 (USD Million)
FIG. 71 Europe biopharmaceuticals CMO & CRO market, 2016 - 2028 (USD Million)
FIG. 72 Revenue growth of Germany pharmaceutical industry
FIG. 73 Germany biopharmaceuticals CMO & CRO market, 2016 - 2028 (USD Million)
FIG. 74 France biopharmaceuticals CMO & CRO market, 2016 - 2028 (USD Million)
FIG. 75 Factors supporting contract manufacturing/research in Asian countries
FIG. 76 Asia Pacific biopharmaceuticals CMO & CRO market, 2016 - 2028 (USD Million)
FIG. 77 China biopharmaceuticals CMO & CRO market, 2016 - 2028 (USD Million)
FIG. 78 India biopharmaceuticals CMO & CRO market, 2016 - 2028 (USD Million)
FIG. 79 Latin America biopharmaceuticals CMO & CRO market, 2016 - 2028 (USD Million)
FIG. 80 Brazil biopharmaceuticals CMO & CRO market, 2016 - 2028 (USD Million)
FIG. 81 Middle East & Africa biopharmaceuticals CMO & CRO market, 2016 - 2028 (USD Million)
FIG. 82 South Africa biopharmaceuticals CMO & CRO market, 2016 - 2028 (USD Million)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界のバイオ医薬品受託製造(CMO)・受託研究(CRO)市場2021-2028:原料別(哺乳類、非哺乳類)、サービスタイプ別(委託製造、委託研究)、製品別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆